JPMorgan's research team shared its top small- and mid-cap biotech stock picks coming out of the second-quarter earnings season.
"Gearing up for the Fall/2H18, we wanted to provide some of our favorite ideas in the SMID-cap space," wrote JPMorgan analyst Anupam Rama in Thursday's note. "We are providing key ideas in various investment strategies following 2Q earnings. Overall, in the SMID biotech, we continue to think selectively is important."
Here are four companies that JPMorgan recommended.